v3.26.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Cash Flows From (Used In) Operating Activities    
Net loss $ (2,428,595) $ (4,320,827)
Non-cash items:    
Stock-based compensation expense 1,040,594 2,609,786
Depreciation expense 56 100
Stock issued for services provided   125,000
Amortization of right of use asset 2,563 854
Expenses allocated by Sanovas on behalf of Company 661,500 654,300
Changes in operating assets and liabilities:    
Increase in accounts payable and accrued liabilities 162,680 187,163
Payment of lease liability (988) (157)
(Increase) in security deposit (1,995)
Increase in accrued interest 3,840 3,840
Total adjustments 1,870,245 3,578,891
Net cash (used in) operating activities (558,350) (741,936)
Cash Flows From Financing Activities    
Proceeds from collection of stock subscription receivable 150,000
Proceeds from sale of common stock 398,000 503,088
Proceeds from exercise of stock options and warrants 210,000
Advances from related parties, net 19,064 34,908
Net cash provided by financing activities 567,064 747,996
Net increase in cash 8,714 6,060
Cash at beginning of period 6,060 0
Cash at end of period 14,774 6,060
Supplemental information:    
Interest paid
Income taxes paid
Operating Lease – at inception 7,689
Retirement of due to Sanovas through the issuance of common stock to Sanovas Ophthalmology LLC (Note C)   666,000
Settlement of account payable through the issuance of common stock $ 150,000